** Shares of drug developer Cytokinetics CYTK.O fall 3.7% to $38.35 premarket
** Rival Bristol Myers Squibb BMY.N said late on Monday its drug, mavacamten, to treat a type of heart disease did not significantly improve functional capacity and symptoms in patients, failing to meet the main goals of a late-stage study
** CYTK is also developing an experimental heart drug, aficamten, to treat non-obstructive form of hypertrophic cardiomyopathy, an inherited condition characterized by thickening of heart muscles
** BofA says most of its prescribers see the two drugs as "more similar than not clinically"
** Brokerage suggests that there might be more discussions about the importance of this class of drugs for all patients, not just those with severe symptoms, due to ongoing uncertainties about the overall potential
** Up to last close, CYTK shares down 15.4%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。